Overview

Definition:
-Endoscopic hemostasis refers to a group of techniques performed during esophagogastroduodenoscopy (EGD) to stop or prevent bleeding from peptic ulcers
-It aims to achieve rapid cessation of hemorrhage, reduce the need for surgery, and improve patient outcomes.
Epidemiology:
-Peptic ulcer bleeding (PUB) affects approximately 150-200 per 100,000 adults annually
-It is a common cause of upper gastrointestinal bleeding (UGIB), with a mortality rate of 2-10%
-Factors like age, comorbidities, and ulcer characteristics influence risk.
Clinical Significance:
-Effective endoscopic hemostasis is crucial for managing acute life-threatening gastrointestinal bleeding
-It directly impacts patient morbidity and mortality, influences hospital stay duration, and reduces the necessity for invasive surgical interventions, making it a cornerstone of modern gastroenterological and surgical practice.

Clinical Presentation

Symptoms:
-Hematemesis (vomiting blood, can be bright red or coffee-ground
-Melena (black, tarry stools
-Hematochezia (less common in upper GI, but can occur with massive bleeding
-Abdominal pain
-Dyspepsia
-Symptoms of hypovolemic shock: dizziness, syncope, weakness, hypotension, tachycardia.
Signs:
-Pallor
-Hypotension
-Tachycardia
-Orthostatic hypotension
-Abdominal tenderness
-Signs of hypovolemic shock
-Rectal examination may reveal melena.
Diagnostic Criteria:
-Diagnosis is based on clinical presentation suggestive of upper GI bleeding, confirmed by the presence of a bleeding peptic ulcer on endoscopy
-Risk stratification scores like the Rockall score and Oakland score help predict outcomes and guide management decisions.

Diagnostic Approach

History Taking:
-Detailed history of bleeding episodes, duration and character of symptoms
-Previous history of ulcers, H
-pylori infection, NSAID or aspirin use
-Comorbidities (liver disease, renal disease, coagulopathy
-Medications (anticoagulants, antiplatelets, NSAIDs
-Alcohol and smoking history.
Physical Examination:
-Assess hemodynamic stability (vital signs, pulse rate, blood pressure, orthostatic measurements
-Assess for pallor, jaundice, or stigmata of chronic liver disease
-Perform abdominal examination for tenderness or masses
-Rectal examination for melena or hematochezia.
Investigations:
-Complete blood count (CBC) to assess hemoglobin and hematocrit
-Coagulation profile (PT, aPTT, INR) to assess bleeding risk
-Liver function tests (LFTs) and renal function tests (RFTs)
-Chest X-ray (to rule out perforation)
-ECG (especially in elderly or those with cardiac risk factors
-Endoscopy (EGD) is the gold standard for diagnosis and treatment.
Differential Diagnosis:
-Esophageal varices bleeding
-Mallory-Weiss tear
-Gastritis or duodenitis
-Esophagitis
-Angiodysplasia
-Dieulafoy's lesion
-Malignancy (gastric or esophageal
-Boerhaave syndrome (esophageal rupture.

Management

Initial Management:
-Immediate resuscitation with intravenous fluids (crystalloids, colloids
-Transfusion of packed red blood cells (PRBCs) to maintain hemoglobin >7 g/dL (or >9 g/dL in patients with significant comorbidities
-Early EGD within 12-24 hours for most patients, or urgently for hemodynamically unstable patients
-Administration of proton pump inhibitors (PPIs) intravenously (e.g., pantoprazole 80 mg bolus followed by 8 mg/hr infusion).
Endoscopic Hemostasis Techniques:
-Combination therapy is often most effective
-Thermal methods: Monopolar electrocoagulation (APC, Heater probe, Bipolar electrocoagulation
-Mechanical methods: Endoscopic clips, Endoscopic band ligation
-Injection therapy: Epinephrine (vasoconstriction, followed by sclerosant like ethanolamine oleate or polidocanol for deeper effect.
Medical Management:
-Intravenous PPI therapy is standard
-If H
-pylori is identified, eradication therapy should be initiated after bleeding control
-Careful review and discontinuation of offending agents like NSAIDs and anticoagulants, with appropriate bridging therapy if needed.
Surgical Management:
-Reserved for patients with persistent or recurrent bleeding despite maximal endoscopic therapy, hemodynamic instability not corrected by resuscitation, or massive transfusions required
-Procedures include vagotomy and pyloroplasty with antrectomy, or gastrectomy depending on ulcer location and extent.
Supportive Care:
-Continuous hemodynamic monitoring
-Close monitoring of fluid balance and urine output
-Nutritional support (may require nasogastric feeding tube if oral intake is compromised
-Monitoring for signs of rebleeding
-Post-endoscopic care to manage pain and nausea.

Complications

Early Complications:
-Rebleeding is the most common complication, occurring in 5-20% of patients
-Perforation (rare, associated with thermal methods
-Esophageal or gastric injury from instrumentation
-Post-polypectomy syndrome (if polyp removal was part of the procedure.
Late Complications:
-Stricture formation (rare, usually from thermal injury or previous surgery
-Chronic anemia from recurrent minor bleeding
-Gastric outlet obstruction if ulcer is near the pylorus and heals with scarring.
Prevention Strategies:
-Aggressive PPI therapy post-endoscopy
-Risk stratification to identify high-risk patients
-Careful selection of endoscopic modality based on ulcer characteristics
-Prompt recognition and management of rebleeding
-Judicious use of NSAIDs and anticoagulants.

Prognosis

Factors Affecting Prognosis:
-Severity of bleeding
-Hemodynamic stability at presentation
-Presence of comorbidities (especially cardiovascular disease, renal failure, liver cirrhosis
-Age
-Ulcer size and location
-Stigmata of recent hemorrhage on endoscopy (e.g., active bleeding, visible vessel
-Need for surgery.
Outcomes:
-With effective endoscopic hemostasis and appropriate management, mortality rates can be reduced to <2%
-Rebleeding rates vary but are significantly lower than historical rates without intervention
-Surgical intervention carries higher morbidity and mortality.
Follow Up:
-Patients with peptic ulcer bleeding require follow-up to ensure complete healing, address underlying causes (e.g., H
-pylori eradication, NSAID cessation
-Repeat endoscopy may be indicated for high-risk lesions or recurrent symptoms
-Long-term PPI therapy may be necessary for select patients.

Key Points

Exam Focus:
-Understand the indications for endoscopic therapy in PUD bleeding
-Differentiate between injection, thermal, and mechanical hemostasis techniques
-Know the management of high-risk ulcers (Forrest Ia, Ib, IIa, IIb
-Recognize factors predicting rebleeding and indications for surgery
-Remember the importance of IV PPI infusion.
Clinical Pearls:
-Always assess hemodynamic stability first
-Use combination therapy (e.g., epinephrine injection followed by clip or thermal coagulation) for high-risk stigmata
-Consider octreotide infusion for variceal bleeding, but PPIs are key for PUD
-Surgical consultation is crucial for refractory bleeding
-Post-endoscopic PPI therapy is vital.
Common Mistakes:
-Delaying endoscopy in unstable patients
-Inadequate resuscitation
-Not using IV PPI infusion appropriately
-Failure to identify and manage high-risk stigmata of bleeding
-Discharging patients without adequate follow-up or treatment for underlying causes
-Over-reliance on injection therapy alone for actively spurting vessels.